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Background and objectives: CYP3A4 expression varies up to 100-fold among 
individuals, and, to date, genetic causes remain elusive. As a major drug 
metabolising enzyme, elucidation of such genetic causes would increase the 
potential for introducing personalised dose-adjustment of therapies involving 
CYP3A4 drug substrates. The fetal CYP3A isoform, CYP3A7, is reported to be 
expressed in approximately 10% of European adults and may contribute to the 
metabolism of endogenous substances and CYP3A drug substrates, yet little is 
known about the distribution of variants associated with adult expression. 
 
Methods: We resequenced the exons, flanking intronic regions, regulatory 
elements and 3’UTR of CYP3A4 in five Ethiopian populations and incorporated 
data from The 1000 Genomes Project. Using bioinformatic analysis we 
assessed likely consequences of observed CYP3A4 genomic variation. We also 
undertook the first extensive geographic survey of alleles associated with adult 
expression of CYP3A7: CYP3A7*1C and CYP3A7*1B.  
 
Results and conclusions: Ethiopia contained 60 CYP3A4 variants (26 novel) 
and more variants >1% than all non African populations combined. No non 
synonymous mutation was found in homozygous form or >2.8% in any 
population. 79% of haplotypes contained 3’ UTR and/or regulatory region 
variation with striking pairwise population differentiation highlighting potential for 
inter-ethnic variation in CYP3A4 expression. Conversely, coding region 
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variation revealed that there is unlikely to be great inter-ethnic variation in the 
type of CYP3A4 protein produced.  CYP3A7*1C, was found at up to 17.5% in 
North African populations and in significant LD with CYP3A5*3 indicating that 
adult expression of the fetal isoform is likely to be accompanied by reduced or 
null expression of CYP3A5. 
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The human CYP3A subfamily is one of the most versatile of the 
biotransformation systems. Expressed predominantly within the liver and 
intestine, CYP3A enzymes contribute to the first pass systemic metabolism of 
more drugs than any other P450, an estimated 60% of those available [1,2]. 
Their associated genes are located in a cassette at chromosome 7q21-22. 
CYP3A enzymes also facilitate the metabolism and biosynthesis of other 
xenobiotics and endogenous substances including cholesterols, bile acids, 
vitamin D and steroid hormones [2, 3]. 
 
There are four functional CYP3A isoforms in humans: CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43 [4, 5]. CYP3A4, the major adult isoform, comprises the 
bulk of adult hepatic P450 and up to 95% of hepatic CYP3A content [2, 6-8].  
 
The predominant CYP3A in the foetal liver, CYP3A7 is down regulated after 
birth and gradually replaced by CYP3A4, contributing on average just 2% to the 
adult hepatic CYP3A mRNA pool [7]. However, recently it has been accepted 
that CYP3A7 expression in the adult liver and intestine is polymorphic; with 11% 
of adult Europeans reported to belong to a distinct subgroup with a high 
CYP3A7 expression phenotype [7, 9-11]. This has been attributed to two 
regulatory region polymorphisms; CYP3A7*1B and CYP3A7*1C [10]. In the 
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foetal liver CYP3A7 is a major source of 16α-hydroxydehydroepiandrosterone 
(16α-OH DHEA) and its sulphated analog 16α-OH DHEAS, estriol precursors 
fundamental during pregnancy [12, 13]. CYP3A7 also has high catalytic activity 
for 16α-hydroxylation of estrone sulphate, the biologically inactive sulphated 
form of estrone [14, 15].  
 
CYP3A5 is polymorphic in the adult due to non functional alleles, namely 
CYP3A5*3, CYP3A5*6 and CYP3A5*7, that vary in frequency among ethnic 
groups. The most common, CYP3A5*3, is found at highest frequency in non-
African populations such that only approximately 20% of Europeans exhibit 
hepatic expression [1, 8, 16]. CYP3A5 contributes approximately 4% to hepatic 
CYP3A content in CYP3A5*3 homozygotes [16-18].  
 
CYP3A43, a fourth member of the sub-family is a minor isoform that undergoes 
extensive alternative splicing such that most transcripts are non functional [5, 
19, 20]. 
 
Hepatic and intestinal CYP3A expression may vary up to 100-fold [1, 21-23]. 
60-90% of this variation is hypothesised to be due to genetic variation within the 
CYP3A locus [22] and may have considerable impact on drug 
pharmacokinetics, altering drug safety and efficacy particularly for substrates 
metabolised primarily by CYP3A enzymes and with narrow therapeutic indices 
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[24]. Identification of CYP3A variants causative of clinically variable phenotypes 
could offer potential for improving predictions of drug safety and efficacy [1, 24, 
25]. 
 
As the major adult CYP3A isoform, variable expression of CYP3A4 is of 
relevance in healthcare. To date, genetic causes of wide variation in CYP3A4 
expression remain elusive and their elucidation would separate genetic causes 
of variation from environmental determinants and increase the potential for 
introducing personalised dose-adjustment of therapies involving CYP3A4 drug 
substrates.  
 
Variable expression of CYP3A enzymes has also been implicated in the risk of 
hormone sensitive cancers of the breast and prostate. CYP3A enzymes have 
numerous roles in steroidogenesis; CYP3A4, CYP3A5 and CYP3A43 enzymes 
catalyse the 2β-, 6β -, and 15β - hydroxylation of testosterone, leading to the 
formation of less biologically active metabolites [26, 27]. CYP3A4 and CYP3A5 
gene variants have been associated with higher-grade prostate cancer tumours 
in ‘Caucasians’ and African Americans [28-31], and the early onset of puberty, a 
known risk factor for breast cancer [32].  
 
Significantly reduced levels of steroid hormones associated with CYP3A7*1C 
has prompted further speculation as to whether adult expression of CYP3A7 is 
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also associated with risk of such hormone sensitive cancers of the breast and 
prostate [33]. Unfortunately, little is known about the distribution of either 
CYP3A7*1B and CYP3A7*1C. Reported frequencies are predominantly from 
studies of European sample sets [10, 11, 16] and data available from The 
International HapMap project and The National Center for Biotechnology 
Information are currently incomplete or reported as ‘suspect’ [34, 35]. 
 
Of interest, given the extremely wide range of inter-individual expression levels, 
paucity of proposed environmental determinants and its importance as a drug 
metabolising enzyme, there are only two reports of CYP3A4 null alleles: 
CYP3A4*20, found in four heterozygous individuals from the same family [36] 
and CYP3A4*6 found in two heterozygous individuals [37, 38]. Thus, unlike 
CYP3A5, for which many non-expressing individuals are known, CYP3A4 may 
be essential for maintaining life. Excluding this study, 81 allelic variants have 
been reported in the genomic region extending from the most distal upstream 
enhancer to the 3’ UTR. Only two non-synonymous (NS) variants have been 
identified in homozygous form [38, 39].  
 
Establishing the nature and extent of variation in CYP3A4 and the implications 
for healthcare is important. We contribute to this undertaking by: a) re-
sequencing the gene’s exons, flanking intronic regions, regulatory elements and 
3’UTR in populations likely to evidence substantial genomic variation and b) 
bioinformatic analysis of the frequencies, distribution and likely consequences 
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of observed genomic variation. Our findings should provide a firm foundation for 
undertaking future in vivo and in vitro expression analysis. We adopt the 
approach of Browning et al, (2010) [40] by characterising CYP3A4 genomic 
variation within five diverse ethnic groups from Ethiopia and extend it to include 
data on 14 other populations from around the world using sequencing data 
obtained from The 1000 Genomes Project. In addition, because it has been 
reported that CYP3A7 alleles are expressed in up to 11% of European adults 
we undertook the first extensive geographic survey of alleles associated with 
adult expression of this gene (CYP3A7*1C and CYP3A7*1B).  
Finally, since CYP3A enzymes overlap considerably in their metabolic activities 
involving both endogenous and exogenous substances and have a) multiple 
roles in steroidogenesis (with the consequence that different combinations of 
CYP3A alleles can produce a range of phenotypes and b) potential implications 
for tacrolimus and cyclosporine dose in post-transplant care we analysed 
possible interactions of common polymorphisms within the CYP3A7, CYP3A5 
and CYP3A4 cassette.  
 
The  association between the CYP3A5*3 genotype and tacrolimus dose  is well 
established [41-45] with CYP3A5*1A/*1A (expresser) and CYP3A5*1A/*3 
individuals exhibiting clearance rates for tacrolimus 25-45% greater than 
CYP3A5*3/*3 (non-expresser) individuals, thus requiring significantly higher 
drug doses to achieve target drug concentration and prevent graft rejection 







Ethiopian DNA samples were collected and prepared according to [40]. 
Samples comprised Afar (n = 76), Anuak (n =76), Maale (n = 76), Oromo (n = 
76) and Amhara (n = 77).  
 
CYP3A4 genotypes of 1094 individuals (61 African Americans, 89 British, 60 
Colombian, 87 Europeans, 93 Finnish, 97 Han Chinese, 89 Japanese, 97 Luhya 
from Kenya, 66 Mexican Americans, 55 Puerto Ricans, 100 Southern Han 
Chinese, 14 Spanish, 98 Tuscans, 88 Yoruba) from May 2011 sequencing calls 
(sequence and alignment release 20101123) of The 1000 Genomes Project 
were analysed. This release is based on the GRCh37 assembly of the human 
genome and is available in VCF4.0 format (http://www.1000genomes.org/data). 
 
For the geographical survey of CYP3A7*1B and CYP3A7*1C, samples from the  
collection maintained by The Centre for Genetic Anthropology collected as 
described for the Ethiopian datasets were analysed. They comprised: 131 
Algerians, 65 Anatolian Turks, 71 Armenians, 83 Ashkenazi Jews, 81 British, 
287 Cameroonians, 51 Congolese, 83 Friesians, 132 Ghanaians, 244 
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Malawians, 80 Moroccan Berbers, 88 Moroccan Jews, 94 Mozambiquans, 79 
Nigerians, 123 Senegalese, 62 Sephardic Jews, 37 South African Bantu 
speakers, 229 Sudanese, 48 Tanzanians, 39 Ugandan Bantu speakers, 113 
Yemeni and 41 Zimbabweans. Details of collection locations are provided in 
Supplementary Material S1, Table S1. 
 
Individuals carrying alleles associated with adult expression of CYP3A7 were 
further genotyped to determine their predicted CYP3A5 expression status. 
CYP3A4/CYP3A7 haplotypes were inferred by pooling Ethiopian CYP3A7 and 
CYP3A4 regulatory region variation data. 
 
Amplification and sequencing of CYP3A4 
 
Amplification and sequencing conditions for all exons, flanking regions of 
adjacent introns, the 3’ UTR and 5’ regulatory regions are described in 
Supplementary Material S2. All 13 exons of CYP3A4, flanking regions of 
adjacent introns and the 3’ UTR were sequenced. Upstream of the gene, 
approximately 500 nucleotides of the promoter were sequenced in addition to 
the two upstream enhancers: the xenobiotic responsive enhancer module 
(XREM) at -7.7 kb to -7.9 kb upstream [47], and the constitutive liver enhancer 
module 4 (CLEM4) at -10.9 kb to -11.4 kb upstream [48]. All primers are 




Amplification of CYP3A7 
 
CYP3A7*1C comprises seven SNPs that occur together in complete Linkage 
Disequilibrium (LD) due to a gene conversion event: -232A>C (rs45446698), -
262T>A (rs11568826), -270T>G (rs11568825), -281T>C (rs45467892), -
282T>C (rs45575938), -284T>A (rs4594802) and -291G>T (rs11568824) [16]. 
The seven SNPs are hereafter referred to collectively as CYP3A7*1C. 
CYP3A7*1B (rs45465393) is a C>T transition 314 nucleotides upstream of the 
translation start site [16].  
 
PCR amplification was undertaken as described in Supplemental Material S2,  
using the primers 5’–GGCATAGGTAAAGATCTGTAGGCAT-3’ and 5’–
AACTTTGGGATGCTGAGCAG-3’ at an annealing temperature of 56°C 
generating an amplicon of 692 nucleotides. 492 nucleotides of this amplicon 








Genotyping for CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272) and CYP3A5*7 
(rs41303343) within Moroccan Berbers and Algerians was undertaken by 
Kbioscience UK (www.kbioscience.co.uk). 12 µl of genomic DNA (per sample) 




For CYP3A4 data, pairwise LD was assessed by the D’ parameter and the 
logarithm (base 10) of odds score (LOD) using Haploview Software v4.2 [49]. 
CYP3A4 rare variants (minor allele frequency <0.001) were excluded. LD was 
assessed using the pooled world dataset, pooled Ethiopian populations 
(Ethiopian dataset) and each individual population separately. For CYP3A7 and 
CYP3A5 data, LD was measured using Arlequin 3.11 Software [50]. Arlequin 
3.11 Software was also used to test for departure of genotype frequencies from 
Hardy Weinberg Equilibrium (HWE), calculate hierarchical FST statistics and 
infer genetic distances between populations as represented by population 
pairwise FST values. The following were calculated using DNAsp 5.10 software 
[51]: Tajima’s D [52] and Fu and Li’s [53] tests of neutrality, gene diversity (h), 
nucleotide diversity (π), and Fisher’s Exact Test. Analysis of variance (ANOVA) 
and Tukey’s multiple comparison tests were undertaken using the Minitab 15 
Software (www.minitab.com/en-US/default.aspx) and Sign Tests undertaken 




Haplotypes were inferred from unphased population genotype data using Phase 
Software version 2.1 [54]. Principal Coordinate Analysis was performed using 
the R statistical package [55] on pairwise similarity matrices, where similarity is 
quantified as being equal to the value of genetic distance subtracted from 1 (1- 
FST). 
 
Inferring haplotypes of CYP3A7*1B, CYP3A7*1C and CYP3A4 
 
Ethiopian data for CYP3A7 and the regulatory region of CYP3A4 were 
combined and haplotypes inferred as described above. Only samples with 
complete genotype data for all variants were included. In total 295 samples with 
complete CYP3A7 genotype data and twelve of the fourteen CYP3A4 regulatory 
region variants were analysed. 
 
Bioinformatic analysis  
 
Putative effects of amino acid substitutions were determined using PolyPhen 2 
Software [56]. Human Splicing Finder (HSF) software (http://www.umd.be/HSF/) 
[57] was used to predict the putative impact of variants within 20 nucleotides of 




CYP3A4 5’ regulatory region variants and CYP3A7*1D (-92G>A) were analysed 
in silico to predict the putative impact of mutations on transcription factor 
binding (TFB) sites using MATCH™ version 8.3, provided by BIOBASE 
(http://www.biobase-international.com/) and the SNPinspector tool within 
Matinspector provided by Genomatix. 60 nucleotides flanking each allele of a 
mutation were used as the sequence input with vertebrate matrices selected 
and a minimum MSS score of 0.8 used as the cut off for matches. SNPinspector 
is only able to analyse single nucleotide changes thus insertions and deletions 





CYP3A4 variation within Ethiopia and populations of The 1000 Genomes 
Project 
 
60 CYP3A4 polymorphic sites were found in Ethiopia (Table 1), including 26 
novel CYP3A4 variants. 89 polymorphic sites were reported by The 1000 
Genomes Project (Table 2).  
 
Ethiopian populations (752 chromosomes) contained twice as many variants at 
frequencies >1% than all non-African populations combined (1122 
chromosomes) and fourteen novel CYP3A4 variants (excluding singletons). 
Eight variants (excluding singletons) were private to a single Ethiopian 
population. The Luhya and Finnish were the only other populations found to 
contain private alleles (three and two each respectively). 26164T>C was the 
only variant that deviated significantly from HWE (within the Maale, χ2 17.74, P 
<0.001 after Bonferroni correction).  
 
Twenty four coding region variants were present in the combined Ethiopian and 
1000 Genomes dataset (referred to hereon as the world dataset), of which 15 
were found on more than one chromosome. No NS mutation was found in 
17 
 
homozygous form or at a frequency >2.8% in any population. All residues 
reported as part of the CYP3A4 active site, interacting with the haem group or 
implicated in binding, stereo specificity and cooperativity of the enzyme were 
monomorphic. One residue of the CYP3A4 phenylalanine cluster was altered by 
a singleton variant in Mexican Americans (15713T>C). A novel variant, 16883T, 
found on a single chromosome in Ethiopia was predicted as creating a 
premature stop codon within exon 8. 
 
Within Ethiopia, the majority of CYP3A4 loci had pair wise D’ values of 1 
indicating complete LD (Fig.1) (LD plots for all other populations can be found 
within Supplemental Material S4). The highest level of LD was observed toward 
the 3’ end of the gene, occurring between the 3’ UTR and exon 7. A line of LD 
was observed across CYP3A4 involving pairs of loci that included -392A>G 
(CYP3A4*1B).  
 
Bioinformatic analysis of CYP3A4 variation 
 
Excluding singletons, PolyPhen 2 predicted seven NS variants to cause benign 




Haplotypes inferred using only coding region variation, so as to restrict the 
haplotype set to those most likely to affect protein structure/function (excluding 
singletons), revealed sixteen coding region haplotypes (Fig. 2). Based on these 
haplotypes, 88% of CYP3A4 chromosomes contained no coding region 
variation. Haplotypes predicted as damaging to CYP3A4 structure/function 
never exceeded 2.2% in any population (Table 4)  
 
Three intronic variants were predicted to impact CYP3A4 splicing: 14319A, 
22050T and 20239A (Table 5). 20239A was particularly interesting due to its 
presence within all populations and high frequency (40-89%) in those of recent 
African origin. 20239A was in high LD with -10502C>T, CYP3A4*1B, 
CYP3A4*1D and -10852C>T indicating that any functional impact of this variant 
would likely be observed in combination with that of regulatory region variation. 
14319A and 22050T did not exceed a frequency of 2% in any population. 
 
Five regulatory region variants were hypothesised to impact CYP3A4 
transcriptional regulation and were present at polymorphic frequencies in 
Ethiopia (Table 6). Each was predicted to destroy/create functional/putative TFB 
sites upstream of the gene with potential implications for transcription factor 
(TF) binding. Haplotypes containing these variants were representative of 






203 CYP3A4 haplotypes were inferred from the world dataset (excluding 
singletons), Supplementary Material S3, Fig. S1 and Table S3. Over half (103) 
of CYP3A4 haplotypes were exclusive to Ethiopia. 99% of haplotypes contained 
multiple variants. 182 haplotypes contained variants that were respectively: 
within the regulatory region (n=134), within the 3’ UTR (n=84), a putative splice 
variant (n=142), or were NS and predicted to impact protein structure/function 
(n=4). Thus, 90% of haplotypes contained variation with potential to impact 
expression and/or protein structure/function. Particularly interesting was the 
presence of regulatory region variation and/or the putative splice variant, 
20239A, on >60% of haplotypes in comparison to coding region variation which 
was found on just 9% of haplotypes. This indicates that altered transcription and 
alternative splicing may be more important in understanding variable CYP3A4 
expression than NS mutations.  
 
Twenty one haplotypes were defined by intronic variation not known or 
predicted to impact CYP3A4 expression/function and can thus be assumed as 
similar in expression and function to CYP3A4*1A until shown otherwise. These 
haplotypes were representative of 87% of European, 79% of Asian, 61% of 
Latin American, 26% of African and 22% of African American chromosomes 
indicating that European populations are most likely to express a CYP3A4 
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protein similar in function to CYP3A4*1A.  This is inclusive of haplotype 94, 
(defined by 19762T, intron 7), the most frequent CYP3A4 haplotype found.  
 
Haplotype 94 ranged in frequency from 5% in the Luhya to 86% in the 
European CEU, > 80% of European chromosomes were established as 
haplotype 94 compared to a maximum of 35% for African chromosomes. The 
Luhya, Yoruba and Anuak were the only populations within which haplotype 94 
was not the most frequent haplotype. Haplotypes most frequent within these 
populations (2, 16, 49 and 150) all contained the promoter variant -392G 
(CYP3A4*1B) and the putative splice variant 20239A 
 
Intragenic and intra population diversity 
 
For the combined world dataset, mean gene (h) and nucleotide (π) diversity 
were consistently highest for CYP3A4 introns (h 0.59 ± 0.26, π 0.00053 ± 
0.00030), lowest for exons (h 0.08 ± 0.07, π 0.00006 ± 0.00005) and 
significantly different among the different gene regions (ANOVA: P<0.001) 
(Fig.3). CYP3A4 introns were significantly more diverse than all other gene 
regions for both π and h, and CYP3A4 exons significantly less diverse than the 
5’ regulatory region for h (Tukey’s post-hoc analysis P<0.05). Fig. 4 depicts 
CYP3A4 h and π for individual populations, the world dataset and the combined 
Ethiopian dataset. Consistent with the hypothesis that modern humans 
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originated within Africa, populations of recent African origin were noticeably 
more diverse than non-African populations. This was true for all regions of 
CYP3A4. The high diversity of CYP3A4 exons within populations of recent 
African origin could indicate that exonic variation is better tolerated within Africa, 
or may simply be a consequence of these older populations having had more 
time within which to accumulate coding region variation. 
  
The diversity of Ethiopian populations was striking; populations placed in order 
of ascending π revealed Ethiopians to be the five most diverse populations for 
the 3’ UTR, and that Ethiopians were the majority among the top five most 
diverse populations for all other gene regions, Supplementary Material S3, 
Table S4.  
 
How different are populations based on CYP3A4 haplotypes? 
 
The majority of populations were significantly differentiated when whole gene 
haplotypes were considered (P<0.0001), Supplementary Material S3, Figure 
S2; Ethiopian populations were significantly differentiated from all populations of 
The 1000 Genomes Project and there was considerable pairwise differentiation 




Analysing each individual gene region separately there was a notable difference 
in pairwise population differentiation based on CYP3A4 coding region variation 
compared to that for the 3’ UTR and 5’ regulatory region , Fig. 5, see also 
Supplementary Material S3, Figures S2-S5. Low population differentiation 
based on coding region variation indicates that unless a consequence of 
regulatory region or alternative splicing substantial ethnic variation in the type of 
CYP3A4 protein produced is unlikely. In contrast, because variation within the 3’ 
UTR and 5’ regulatory region has the potential to impact CYP3A4 expression, 
observed differences among populations suggest potential for ethnic variation in 
the amount of CYP3A4 expressed.  
 
Testing for selection 
 
Tajima’s D and Fu and Li’s D* and F* were negative for all populations 
(Supplementary Material S3, Table S5), a Sign test on the individual results 
yielded P<0.0001 for all three statistics. 
Purifying selection was the prior hypothesis given the rarity of homozygous 
CYP3A4 NS mutations and the lack of reported homozygous null alleles. 
Resequencing CYP3A4 did not reveal an excess of CYP3A4 NS mutations, 
rather it confirmed that CYP3A4 exons are significantly more conserved than 
non coding regions of the gene. It is consequently unlikely that positive 





Distribution of variants associated with adult expression of CYP3A7 
 
Variation found upstream of CYP3A7 
 
CYP3A7*1C was found in African, Middle Eastern and European populations 
ranging in frequency from <1% to a maximum of 17.5% in Moroccan Berbers. 
CYP3A7*1B was observed as a singleton within Friesian and British populations 
confirming the previously reported low frequency distribution of this variant 
(Table 8).  
 
Eight additional variants were found upstream of CYP3A7, six were singletons 
(not shown) and one was the CYP3A7*1D (-49G>A) variant previously reported 
at 1% in Caucasians [16]. CYP3A7*1D was the most frequent CYP3A7 variant 
found, ranging in frequency from 1% in Moroccan Jews to 22% in 
Cameroonians of Mayo Darle  and was the only variant found in all African 
populations studied (Table 8).  
 
Significant deviation from HWE was observed when populations were 
considered separately. CYP3A7*1C deviated significantly within the Senegalese 
Wolof (χ2 63) and Armenians (χ2 16.7), and CYP3A7*1D within the Mayo Darle 
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(χ2 212.04) (Bonferroni correction for multiple tests, P<0.001). No variant was 
identified within all populations. 
 
Are predicted adult expressers of CYP3A7 also predicted to express 
CYP3A5? 
 
Algerian and Moroccan Berber individuals carrying one or more CYP3A7*1C 
alleles were genotyped for CYP3A5*3, CYP3A5*6 and CYP3A5*7 (Table 9). 
CYP3A5*3 was the most common CYP3A5 null allele at 86% in both 
populations. Interestingly, all individuals carrying one or more CYP3A7*1C 
alleles were found to carry at least one CYP3A5*3 allele. More than half were 
predicted CYP3A5 non expressers (CYP3A5*3/*3) and one third were 
CYP3A5*1A/*3 heterozygotes (predicted reduced CYP3A5 expression). Results 
thus provide good evidence that in these populations at least, adult expression 
of CYP3A7 is associated with reduced/null expression of CYP3A5. 
 
Haplotype inference suggested CYP3A7*1C and CYP3A5*3 are present on a 
shared haplotype background, haplotype 6, which is present at 7.1% and 17.9% 
within Algerians and Moroccan Berbers respectively (Table 10). Significant LD 
was observed between the two alleles (D’ 0.85, χ2 6.15, P<0.02, 1 df) with 
evidence of low frequency (<1%) recombination between CYP3A5*3 and 




Does CYP3A7*1C occur on the same haplotype background as CYP3A4 
regulatory region variants? 
 
Combining Ethiopian CYP3A7*1C data with that for CYP3A4 regulatory region 
variation revealed fifteen CYP3A4/CYP3A7 haplotypes, three containing 
CYP3A7*1C (Table 11). CYP3A7*1C was found with CYP3A4*1A more 
frequently than any other CYP3A4 regulatory region variant, occurring together 
on haplotype 13 at a total frequency of 3.1% in Ethiopia. Haplotypes 14 and 15 
were found at <1% in Ethiopia. Haplotype 14, defined by CYP3A7*1C and -
333T in significant LD (D’ 1, χ2 54.18, P<0.001, df 1) was exclusive to the 
Maale, at 1.6%. The functional impact of -333T remains to be determined but it 
was predicted here to destroy a putative glucocorticoid response element 
(GRE) in the CYP3A4 promoter (Table 6). If functional, as has been 
hypothesised [58], the loss of this motif would likely reduce glucocorticoid 
receptor (GR) mediated induction of CYP3A4. 
 
CYP3A4*1B was predicted to create a putative peroxisome proliferator 
response element (PPRE), a binding site for the peroxisome proliferator 
activated receptor (PPAR) family of nuclear receptors (Table 6). This is in 
agreement with reports that CYP3A4*1B increases expression of CYP3A4 as 
PPARs are activating TFs [23, 59-61]. Adults carrying haplotype 15 could thus 




Potential implications of CYP3A7*1D for transcriptional activation of 
CYP3A7 
 
Due to the widespread distribution and high frequency presence of 
CYP3A7*1D, in silico analysis was undertaken to identify any potential for this 
variant to alter CYP3A7 TFB sites. Three putative TFB sites were identified in 
the region containing CYP3A7*1D, the putative impact of this variant on these 
sites is shown in Table 12.  
 
In vitro work using foetal hepatocytes suggests potential for the direct regulation 
of CYP3A7 by the glucocorticoid receptor (GR) [62]. If the GR is involved in 
CYP3A7 regulation, then the functionality of the putative GRE created by 
CYP3A7*1D should be determined, the additional GRE may alter the CYP3A7 
expression profile in carriers of CYP3A7*1D.  
 
AhR is a cytosolic TF [63] and activator of CYP1A1, but is not known to regulate 
any CYP3A [63, 65]. CCAAT enhancer binding proteins (C/EBPs) are regulators 
of CYP3A genes [65]. Therefore there is potential for the -51/-34 motif to be 





Is CYP3A4 a protein essential for life? 
 
Analysis of the world dataset lends weight to a hypothesis that homozygotes for 
CYP3A4 null alleles either do not exist in the adult population or are extremely 
rare, an indication that CYP3A4 expression may be essential. The datasets 
included in this study are collectively among the largest analysed for CYP3A4 
variation and the paucity of exonic variation is consistent with all current reports 
of CYP3A4 variation as is the evidence for purifying selection.  
 
Interestingly, unlike CYP3A5 a near genomic neighbour with similar substrate 
affinities, no homozygotes for NS variants were observed and haplotypes 
predicted as damaging to CYP3A4 structure/function never exceeded 2.2% in 
any population. It is possible that polymorphic expression of CYP3A5 may have 
contributed to evolutionary conservation of CYP3A4, to compensate for 
reduced/null CYP3A5 enzyme activity. Alternatively, CYP3A4 expression may 
simply be exclusively responsible for the essential metabolism/biosynthesis of 
an unknown substrate. Indeed, unique endogenous roles do exist for CYP3A4, 
e.g. in Vitamin D biosynthesis [66, 67]. Determining why CYP3A4 might be an 
essential protein is beyond the scope of this study. However its results indicate 




Implications for understanding variable expression of CYP3A4 
 
Most previous studies have focused on identification and functional assessment 
of individual CYP3A4 variants [e.g. 68-72]. Our results suggest that different 
combinations of alleles may have reinforcing or moderating effects making the 
haplotype rather than the SNP the preferred unit of interpretation.  
 
99% of CYP3A4 haplotypes identified were compound, often comprising 
combinations of variants with potential to impact CYP3A4 expression; 64% 
contained regulatory region variation, often in combination with the putative 
splice variant, 20239A (CYP3A4*1G). High LD between CYP3A4*1G and 
variants upstream of CYP3A4 indicate that any functional impact of this 
polymorphism would likely be observed in combination with that of regulatory 
region variation. This may explain previous associations of CYP3A4*1G with 
both decreased [73-75] and increased CYP3A4 enzymatic activity [76]. NS 
variants including T185S and CYP3A4*15 (previously suggested as causative 
of poor nifedipine metabolism [71]) were also found on compound haplotypes 
containing CYP3A4*1G and regulatory region variation. It is possible that the 
results of earlier in vivo functional studies, investigating individual gene variants, 





79% of haplotypes contained 3’ UTR and/or regulatory region variation with 
striking pairwise population differentiation that highlights the potential 
importance of inter-ethnic variation in CYP3A4 expression, particularly between 
African and non-African populations. Conversely, much less differentiation of 
coding region variation was observed among groups suggesting that there is 
unlikely to be great inter-ethnic variation in the type of CYP3A4 protein 
produced.  
 
Regulatory region variation may enhance or reduce gene expression. Five 
regulatory region variants hypothesised to impact CYP3A4 transcriptional 
regulation were found at polymorphic frequencies within Ethiopian populations, 
CYP3A4*1B, -333C>T, -11185_-11186insTGT, -11131G>A and -10502T>C. 
Each was predicted to destroy/create putative/functional binding sites with 
hypothesised implications for TF binding and CYP3A4 expression. 
 
The impact of 3’ UTR variation remains unknown. One study investigated 
MiRNA regulation of CYP3A4 [77], reporting that MiRNA species are able to 
bind the CYP3A4 3’ UTR with an impact on expression in human cell lines.  
 
At present, ethnic differences in CYP3A4 expression are poorly characterised. 
Better understanding of the effects of polymorphisms in both the CYP3A4 
regulatory region and 3’ UTR, if any, and their frequencies in different ethnic 
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groups should contribute to better selection of subjects to clinical trials of 
CYP3A4 substrate drugs. Intergroup differences may be of particular 
importance in Sub Saharan Africa where genomic diversity is greatest.  
 
Ethiopia is genetically diverse 
 
Consistent with the hypothesis that modern humans migrated out of Africa via 
Ethiopia [78] much of CYP3A4 variation reported in populations outside of 
Ethiopia was present within Ethiopian groups. Considerable novel CYP3A4 
variation was found with more than half of all CYP3A4 entire gene haplotypes 
exclusive to Ethiopia. Measures of diversity consistently placed Ethiopian 
groups among the top five most diverse populations thus emphasising the 
considerable genetic diversity of Ethiopian ethnic groups.   
 
Our work strongly favours Ethiopia as an attractive region in which to seek and 
evaluate novel variants. As a consequence, studies involving Ethiopian 
populations have the potential to make a substantial contribution to knowledge 
of genomic variation within clinically relevant genes.   
 
Adult expression of CYP3A7  




This study represents the most extensive ethno-geographic report of CYP3A7 
variants that have been associated with adult expression [11, 16, 22], implicated 
in the risk/progression of hormone sensitive cancers [33] and thought to have 
potential implications for the administration of CYP3A drug substrates.  
 
CYP3A7*1C has been associated with significantly reduced levels of circulating 
steroid hormones that are known risk factors for and may play a role in the 
aetiology of hormone sensitive cancers [33]. CYP3A7*1C was at high frequency 
among populations of North Africa where, interestingly, average incidence rates 
(per 100,000 age standardised on world population) are 4.5 and 2-fold lower for 
prostate and breast cancer respectively (Algeria, Morocco, Libya, Tunisia and 
Egypt combined) when compared to Europe [79]. North African prostate cancer 
patients are also reported to have more favourable cancer characteristics than 
‘Caucasians’ in general and Africans of Central Africa and the French West 
Indies [80]. 
 
The geographic distribution of CYP3A7*1C suggests that investigating the 
possible association between adult expression of CYP3A7 and the 
risk/progression of hormone sensitive cancer could yield interesting insight into 
the role CYP3A enzymes play in disease causation and progression. Ethnic 
background is recognised as playing a role in the detection, prevalence, 




In the populations studied, predicted adult expression of CYP3A7 occurs on the 
background of a predicted reduced/null expression CYP3A5 phenotype. Adult 
expression of CYP3A7 may exceed CYP3A5 in individuals carrying both 
CYP3A7*1C and CYP3A5*3 alleles [11, 82]. Thus, within the populations of this 
study where CYP3A7*1C is at high frequency, CYP3A7 expression may be 
quantitatively more important than that of CYP3A5. Consequently, association 
studies investigating the impact of CYP3A7*1C should be designed to take 
account of CYP3A5 genotypes.  CYP3A5 and CYP3A7 have different roles in 
steroidogenesis and different combinations of alleles of the two genes are likely 
to have different phenotype outcomes. 
 
The distribution of CYP3A7*1C presented here may also be of practical 
relevance to the administration of CYP3A drug substrates. Adult expression of 
CYP3A7 is likely to be substantial in members of a number of ethnic groups.  
Thus, where the function of CYP3A7 is known to overlap with that of CYP3A4 
and CYP3A5, CYP3A7*1C genotype should be taken into account when 
considering drug choice and dose. This is especially relevant to transplant 
pharmacology involving cyclosporine and tacrolimus. Genotyping for 
CYP3A7*1C may improve initial dosing strategies for transplant patients. This is 
of relevance for example in France where substantial numbers of the North 
African Diaspora live representing one of the largest ethnic minorities at 
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approximately 9% of the general population (The World Factbook: France; 
www.cia.gov/library/publications/the-world-factbook/geos/fr.html).  
 
Our results lend support to recent suggestions that CYP3A polymorphisms and 
their association with clinical conditions will be better understood by adopting a 
CYP3A haplotype approach [33] including multiple polymorphisms of CYP3A4, 
CYP3A5, and CYP3A7, particularly CYP3A7*1C, CYP3A4*1B and CYP3A5*3 
which have previously been associated with altered steroid hormone levels and 
cancer incidence [33]. 
 
CYP3A have multiple roles in steroidogenesis, thus there is likely to be difficulty 
in unravelling the functional impact of individual CYP3A polymorphisms without 
considering others present at the CYP3A locus. Data presented in this study 
suggest that a more rapid shift from researching gene variants to gene 
haplotypes is necessary if pharmacogenetic research is to properly address the 
genomic complexity that is becoming increasingly apparent. By doing so, 
pharmacogenetic research should better contribute to the development of 
personalised/stratified medicine and improved healthcare policy. 
 
Finally, this study is consistent with that of [40] which reported extensive 
variation in CYP1A2 within the peoples of Ethiopia and provides further support 
for the hypothesis that they represent a rich resource for assessing genomic 
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variation, particularly when combined with data from worldwide populations as 
available in The 1000 Genomes project. Furthermore the presence of extensive 
variation outside the coding region, but not within it, supports hypotheses that: 
a) the protein CYP3A4 is essential for the maintenance of life and b) wide inter-
individual differences in levels of expression are likely to be due in large 
measure to genomic variation in the promoter and, possibly, 3’ UTR regions. It 
is possible to speculate that since, so far as we are aware, there are no reports 
of mortality in either adults or children associated with a CYP3A4 mutation that 
if the protein is essential for life it plays an important, and as yet undetected, 
role either at or prior to conception or shortly thereafter notwithstanding that 
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Fig.1 LD across CYP3A4 in the Ethiopian dataset 
 
The strength of LD is based on D’ and LOD (logarithm of the odds) scores and increases with colour from white to blue to red as depicted in Key 1. At the top 
of the figure, the first row of numbers denotes the CYP3A4 variant (Key 2), the second row indicates position of each variant on the chromosome. The space 
between loci is indicated by the white bar at the top of the plot. Numbers within squares are D’ values (multiplied 100-fold). Empty squares indicate D’ of 




Number Chromosome pos. CYP3A4 variant Location Number Chromosome pos. CYP3A4 variant Location
1 99393120 -11386T>A 5' Upstream 39 99365083 16622C>T Intron 7
2 99392921 -11185_-11186insTGT 5' Upstream 40 99364672 17033C>T Intron 8
3 99392865 -11131G>A 5' Upstream 41 99363880 17824_17825delAT Intron 9
4 99392804 -11070G>C 5' Upstream 42 99363813 17892C>G Intron 9
5 99392586 -10852C>T 5' Upstream 43 99363760 17945C>T Intron 9
6 99392451 -10755_delG 5' Upstream 44 99363731 17974A>G Intron 9
7 99392236 -10502C>T 5' Upstream 45 99361626 20079T>C Exon 10
8 99389435 -7701A>G 5' Upstream 46 99361466 20239G>A Intron 10
9 99382128 -394T>C 5' Upstream 47 99361387 20318G>C Intron 10
10 99382096 -392A>G 5' Upstream 48 99361369 20336T>C Intron 10
11 99381998 -333C>T 5' Upstream 49 99359911 21794A>C Intron 10
12 99381919 -215T>A 5' Upstream 50 99359800 21905C>T Exon 11
13 99381766 -62 C>A 5' Upstream 51 99359734 21971A>G Exon 11
14 99381639 66 C>G Exon 1 52 99359655 22050C>T Intron 11 
15 99381603 102 T>C Intron 1 53 99358693 23012G>A Intron 11 
16 99381561 144 A>G Intron 1 54 99358615 23090C>T Intron 11 
17 99377848 3857C>T Intron 1 55 99358524 23181T>C Exon 12
18 99377827 3873_3875delATT Intron 1 56 99355975 25730A>G Intron 12
19 99375702 6003G>A Exon 3 57 99355957 25748C>T Intron 12
20 99375554 6151G>A Intron 3 58 99355870 25835G>A Intron 12
21 99375547 6158 T>A Intron 3 59 99355789 25916T>G Exon 13
22 99370083 11522C>T Intron 4 60 99355785 25920T>A Exon 13
23 99367867 13838 G>C Intron 4 61 99355612 26093T>C 3' UTR
24 99367727 13978 G>A Intron 5 62 99355541 26164T>C 3' UTR
25 99367427 14278G>A Exon 6 63 99355522 26184C>T 3' UTR
26 99367392 14313G>C Exon 6 64 99355490 26215C>A 3' UTR
27 99367386 14319G>A Intron 6 65 99355427 26278C>T 3' UTR
28 99367339 14366T>G Intron 6 66 99355372 26335T>C 3' UTR
29 99366093 15612C>G Exon 7 67 99355278 26427C>T 3' UTR
30 99366068 15637C>T Exon 7 68 99355185 26520C>T 3' UTR
31 99366048 15658A>T Exon 7 69 99355073 26632C>T 3' UTR
32 99366047 15658A>G Exon 7 70 99355072 26633G>A 3' UTR
33 99365983 15722T>C Exon 7 71 99354989 26716_delT 3' UTR
34 99365948 15757A>C Intron 7 72 99354947 26758T>C 3' UTR
35 99365943 15762G>T Intron 7 73 99354864 26841C>A 3' UTR
36 99365913 15792T>C Intron 7 74 99354808 26897A>T 3' UTR
37 99365892 15813T>C Intron 7 75 99354661 27044C>G 3' UTR
38 99365876 15829A>G Intron 7
































C>G Predicted effect 
on CYP3A4 
structure/function3 
Exon 13 13 12 11 11 10 7 7 7 7 7 6 6 3 1 
Amino Acid 












1                                 
2                               Undamaged 
3                               
Probably 
Damaged 
4                               Undamaged 
5                               Undamaged 
6                               Possibly Damaged 
7                               Undamaged 
8                               Undamaged 
9                               Possibly Damaged 
10                               Undamaged 
11                               Undamaged 
12                               Undamaged 
13                               Undamaged 
14                               
Probably 
Damaged 
15                               Undamaged 
16                               Undamaged 
 
1 Position from base A in initiation codon (A in ATG is considered as +1). 
2 White cell, allele observed in CYP3A4*1A; grey cell, derived allele. 
3 Predictions made using PolyPhen2 based on single amino acid alterations. 

























3'UTR 5' Upstream Exons Introns
π
Fig. 4 Gene diversity (h) and nucleotide diversity (π) based on haplotypes inferred for the entire CYP3A4 gene and CYP3A4 introns, exons 3’ UTR and 5’ 
regulatory region
 
Error bars indicate standard error of the mean. ASW, African American; CEU, European; CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; 
FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; 



























3'UTR 5' regulatory region Exonic Intronic Whole Gene
Fig. 5 PCO plots illustrating genetic distances (Fst) between populations calculated using: CYP3A4 a) 









































ASW, African American; CEU, European; CHB, Han Chinese; CHS, Southern Han Chinese; CLM, 
Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican 
American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; EAM, Amhara; EAN, Anuak; 















































































































Numbers in brackets indicate the number of chromosomes. Italics indicate variants found on more than one chromosome that were private to a population. 
Shaded rows indicate variants found both in Ethiopia and populations of The 1000 Genomes Project. n, the number of chromosomes carrying the variant 
allele. f, frequency of the variant allele. 
 
CYP3A4 Variant 














Anuak              
(152) 
Maale           
(150) 




n f n f n f n f n f n f 
26897A>T 99354808 28371763 3' UTR   5 0.033 4 0.026 0 0.000 8 0.053 5 0.034 22 0.029 
26841C>A 99354864   3' UTR   0 0.000 1 0.007 4 0.026 3 0.020 1 0.007 9 0.012 
26716_delT 99354989 28969391 3' UTR   31 0.204 33 0.217 62 0.408 52 0.347 28 0.192 206 0.274 
26633G>A 99355072 34141651 3' UTR   0 0.000 2 0.013 0 0.000 1 0.007 1 0.007 4 0.005 
26632C>T 99355073 28988604 3' UTR   3 0.020 4 0.026 9 0.059 6 0.040 3 0.021 25 0.033 
26537C>T 99355168   3' UTR   0 0.000 0 0.000 0 0.000 1 0.007 0 0.000 1 0.001 
26335T>C 99355372   3' UTR   0 0.000 3 0.020 0 0.000 6 0.040 4 0.027 13 0.017 
26184C>T 99355522   3' UTR   0 0.000 3 0.020 0 0.000 0 0.000 0 0.000 3 0.004 
26164T>C 99355541   3' UTR   0 0.000 0 0.000 0 0.000 4 0.027 0 0.000 4 0.005 
26076A>T 99355629 35494189 3' UTR   0 0.000 0 0.000 1 0.007 0 0.000 0 0.000 1 0.001 
25920T>A 99355785   Exon 13 S495T 0 0.000 1 0.007 0 0.000 0 0.000 2 0.014 3 0.004 
25916T>G 99355789   Exon 13   2 0.013 2 0.013 0 0.000 0 0.000 4 0.027 8 0.011 
25748C>T 99355957 147972695 Intron 12   2 0.013 1 0.007 5 0.033 1 0.007 3 0.021 12 0.016 
25730A>G 99355975 3735451 Intron 12   71 0.467 69 0.454 111 0.730 93 0.620 58 0.397 402 0.535 
23090C>T 99358615 12721620 Intron 11   9 0.059 13 0.086 36 0.237 23 0.153 14 0.096 95 0.126 
22046A>G 99359659   Intron 11   0 0.000 0 0.000 0 0.000 0 0.000 1 0.007 1 0.001 
21971A>G 99359734   Exon 11 M395V 0 0.000 0 0.000 0 0.000 2 0.013 0 0.000 2 0.003 
20409C>T 99361296   Intron 10   0 0.000 1 0.020 0 0.000 0 0.000 0 0.000 1 0.001 
20336T>C 99361369 34738177 Intron 10   5 0.033 1 0.007 2 0.013 4 0.027 4 0.027 16 0.021 
20318G>C 99361387 4986911 Intron 10   2 0.013 1 0.007 9 0.059 1 0.007 4 0.027 17 0.023 
20239G>A (*1G) 99361466 2242480 Intron 10   66 0.434 65 0.428 112 0.737 83 0.553 59 0.404 385 0.512 
17974A>G 99363731 34314536 Intron 9   2 0.013 1 0.007 6 0.039 1 0.007 3 0.021 13 0.017 
17892C>G 99363813 10267228 Intron 9   29 0.191 28 0.184 49 0.322 29 0.193 24 0.164 159 0.211 
17824_17825delAT (*1S) 99363880 56153749 Intron 9   0 0.000 0 0.000 2 0.013 0 0.000 0 0.000 2 0.003 
17712A>G 99363993   Intron 9   0 0.000 0 0.000 0 0.000 1 0.007 0 0.000 1 0.001 
17033C>T 99364672 12721624 Intron 8   0 0.000 0 0.000 2 0.013 0 0.000 0 0.000 2 0.003 
16883G>T 99364882   Exon 8 E242STOP  1 0.007 0 0.000 0 0.000 0 0.000 0 0.000 1 0.001 
16622C>T 99365083 4646437 Intron 7   67 0.441 69 0.454 114 0.750 91 0.607 62 0.425 403 0.536 
15792T>C 99365913 4987160   Intron 7   0 0.000 2 0.013 5 0.033 0 0.000 2 0.014 9 0.012 
15762G>T 99365943 2687116 Intron 7   91 0.599 98 0.645 29 0.191 58 0.387 88 0.603 364 0.484 
15757A>C 99365948   Intron 7   0 0.000 0 0.000 1 0.007 1 0.007 0 0.000 2 0.003 
15658A>T 99366048   Exon 7 Q200H  0 0.000 2 0.013 0 0.000 0 0.000 2 0.014 4 0.005 
15637C>T 99366068 4987159 Exon 7   2 0.013 3 0.020 11 0.072 13 0.087 3 0.021 32 0.043 
14366T>G 99367339 12721623 Intron 6    1 0.007 0 0.000 0 0.000 1 0.007 0 0.000 2 0.003 
14278G>A (*15A) 99367427 4986907 Exon 6 R162Q  0 0.000 2 0.013 1 0.007 0 0.000 1 0.007 4 0.005 
14277C>T 99367428 57409622 Exon 6  R162W  0 0.000 0 0.000 0 0.000 0 0.000 1 0.007 1 0.001 
14228G>C 99367477   Exon 6 M145I 0 0.000 1 0.007 0 0.000 0 0.000 0 0.000 1 0.001 
13978 G>A 99367727   Intron 5   0 0.000 0 0.000 0 0.000 2 0.013 1 0.007 3 0.004 
13970 T>C 99367735   Intron 5   1 0.007 0 0.000 0 0.000 0 0.000 0 0.000 1 0.001 
13838 G>C 99367867 12721618 Intron 4   0 0.000 0 0.000 3 0.020 0 0.000 0 0.000 3 0.004 
6158 T>A 99375547 12721619 Intron 3   1 0.007 0 0.000 2 0.013 4 0.027 1 0.007 8 0.011 
4064 T>G 99377641   Exon 2 L47V 0 0.000 1 0.007 0 0.000 0 0.000 0 0.000 1 0.001 
3873_3875delATT 99377827:99363881 71581993 Intron 1    0 0.000 0 0.000 0 0.000 4 0.027 1 0.007 5 0.007 
144 A>G 99381561 35587942 Intron 1    0 0.000 0 0.000 1 0.007 4 0.027 1 0.007 6 0.008 
102 T>C 99381603   Intron 1    7 0.046 2 0.013 5 0.033 1 0.007 8 0.055 23 0.031 
66 C>G 99381639   Exon 1   1 0.007 0 0.000 0 0.000 3 0.020 1 0.007 5 0.007 
-32 T>C  99381736   5'upstream   0 0.000 0 0.000 0 0.000 0 0.000 1 0.007 1 0.001 
-62 C>A  99381766 12721636 5'upstream   9 0.059 3 0.020 0 0.000 4 0.027 10 0.068 26 0.035 
-247G>A 99381952   5'upstream   0 0.000 0 0.000 0 0.000 0 0.000 1 0.007 1 0.001 
-333C>T 99381998   5'upstream   0 0.000 0 0.000 0 0.000 2 0.013 0 0.000 2 0.003 
-392A>G 99382096 2740574 5'upstream   53 0.349 49 0.322 125 0.822 71 0.473 52 0.356 350 0.465 
-7949G>A 99389685   5'upstream   0 0.000 0 0.000 1 0.007 0 0.000 0 0.000 1 0.001 
-10502C>T 99392236 115518242 5'upstream   1 0.007 1 0.007 4 0.026 0 0.000 1 0.007 7 0.009 
-10755_delG 99392451   5'upstream   2 0.013 0 0.000 0 0.000 1 0.007 1 0.007 4 0.005 
-10852C>T 99392586 74370707 5'upstream   0 0.000 0 0.000 2 0.013 1 0.007 0 0.000 3 0.004 
-11070G>C 99392804 36015827 5'upstream   0 0.000 2 0.013 1 0.007 0 0.000 0 0.000 3 0.004 
-11073T>C 99392807   5'upstream   0 0.000 0 0.000 0 0.000 1 0.007 0 0.000 1 0.001 
-11131G>A 99392865 112639771 5'upstream   0 0.000 0 0.000 4 0.026 0 0.000 0 0.000 4 0.005 
-11185_-11186insTGT 99392921:99392922 34401238 5'upstream   3 0.020 5 0.033 0 0.000 0 0.000 0 0.000 8 0.011 
-11386T>A 99393120 34020359 5'upstream   0 0.000 2 0.013 5 0.033 3 0.020 0 0.000 10 0.013 
                 
Table 3 The predicted effect of CYP3A4 non synonymous variants on protein structure and function as determined by PolyPhen2 
 
ASW, African American; CEU, European; CHS, Southern Han Chinese; FIN, Finnish; GBR, British; JPT, Japanese; LWK, Luhya; MXL, Mexican American; 
PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo 
CYP3A4 Variant Exon Amino acid change Frequency Predicted effect on CYP3A4 structure/function 
6003G>A 3 G56D 0.005 FIN, 0.005 TSI Probably damaging 
14278G>A 6 R162Q 
0.007 EAN, 0.007 EOR, 0.008 ASW, 0.008 MXL, 0.012 
EAM, 0.028 YRI 
Benign 
14313G>C 6 D174H 0.009 PUR, 0.017 GBR Benign 
15612C>G 7 T185S 0.022 JPT Possibly damaging 
15658A>T 7 Q200H 0.005 CHS, 0.011 JPT, 0.013 EAM, 0.014 EOR Benign 
15722T>C 7 S222P 0.011 FIN Possibly damaging 
20079T>C 10 L293P 0.015 CHS, 0.017 JPT Benign 
21905C>T 11 L373F 0.026 LWK Benign 
21971A>G 11 M395V 0.013 EAM Benign 
23181T>C 12 M445T 0.006 CEU, 0.006 GBR, 0.008 CLM, 0.011 FIN Probably damaging 
25920T>A 13 S495T 0.007 EAM, 0.014 EOR Benign 
Table 4 Frequencies of CYP3A4 coding region haplotypes 











1 0.951 0.994 1.000 0.985 0.983 0.973 0.978 1.000 0.961 0.928 0.992 0.945 0.990 0.892 0.967 0.934 0.921 0.880 0.911 
2                             0.007     0.020 0.007 
3           0.005             0.005             
4 0.008                   0.008     0.028   0.013 0.007   0.007 
5             0.017         0.009               
6                 0.022                     
7 0.041       0.008         0.046   0.045 0.005 0.080 0.013 0.020 0.072 0.087 0.021 
8                               0.013     0.014 
9           0.011                           
10       0.010         0.006                     
11       0.005         0.011                     
12                   0.026                   
13                                   0.013   
14   0.006     0.008 0.011 0.006                         
15                             0.013 0.013     0.027 
16                               0.007     0.014 
ASW, African American; CEU, European; CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, 
Japanese; LWK, Luhya; MXL, Mexican American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, 
Oromo. 




Distance from exon 
(nucleotides) 





Predicted impact on splicing1 
25835A Intron 12 19 0.015 LWK None None 
23090T Intron 11 11 
0.008 MXL; 0.025 CLM; 0.059 EAF; 0.073 PUR; 0.086 EAM; 0.096 
EOR; 0.153 EML; 0.232 LWK; 0.237 EAN; 0.295 ASW; 0.330 YRI 
None None 
22050T Intron 11 9 0.011 GBR;0.008 MXL None 
+7 nucleotides added to exon 11 due to 
creation of putative alternative splice site 
20239A Intron 10 12 
0.705 ASW;0.052 CEU; 0.247 CHB; 0.245 CH; 0.292 CLM; 0.098; 
0.434 EAF; 0.428 EAM; 0.737 EAN; 0.553 EML; 0.404 EOR; 0.070 
FIN; 0.079 GBR; 0.143 IBS; 0.281 JPT; 0.997 LWK; 0.417 MXL; 
0.318 PUR; 0.082 TSI; 0.858 YRI 
Possible disruption 
+11 nucleotides added to exon 10 due to 
creation of putative alternative splice site 
14319A Intron 6 5 0.025 ASW; 0.015 LWK; 0.009 PUR; 0.011 YRI Possible disruption None 
14209G Intron 5 17 0.005 CHB None None 
13970G Intron 5 10 0.007 EAF None None 
13838C Intron 4 9 0.020 EAN; 0.010 LWK; 0.009 PUR; 0.023 YRI None None 
11975C Intron 3 18 0.005 CHS None None 
 
ASW, African American; CEU, European; CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, 
Japanese; LWK, Luhya; MXL, Mexican American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, 
Oromo. 1 Predictions made using Human Splicing Finder Software. 





Possible Implications for CYP3A4 expression 
Predicted effect on 





-333T EML 1.3% Promoter Disruption of putative GRE 
Hypothesised that a GRE exists within the promoter (El 
Sankary et al., 2002) Reduced expression 
-392A 
EAN, EOR, EML, 
EAF,  EAM ≤ 82% 
Promoter Creation of putative PPRE 
Increased and decreased expression observed in vitro 
(Wandel et al., 2000; Spurdle et al., 2002; Amirimani et al., 
2003; Rodríguez-Antona et al., 2005) Increased expression 
-10502C 




Creation of putative C/EBP 
site 
Evidence that C/EBPα up regulates CYP3A4 by direct binding 
at promoter (Rodríguez-Antona et al., 2003; Bombail et al., 
2004). Increased expression 
-11131A EAN 2.6% CLEM4 Disruption of functional Ebox 
Site directed mutagenesis of this E-box reported to reduce 
enhancer activity by 43% in vitro (Matsumara et al., 2004) Reduced expression 
-11185insTGT EAM, EAF ≤3.3% CLEM4 Disruption of functional Ebox 
-11185_-11186insTGT reported to reduce enhancer activity in 
vitro (Matsumara et al., 2004) Reduced expression 
 
EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo; GRE, Glucocorticoid Response Element; PPRE, Peroxisome Proliferator Response 
Element; C/EBP, CCAAT Enhancer Binding Protein. 1 Predictions made using MATCH and Matinspector. 




















-392   
A>G 
-333   
C>T 
-247   
G>A 





























1                             0.625 0.143 0.570 0.566 0.508 0.482 
2                             0.023 0.000 0.070 0.057 0.025 0.035 
3                             0.289 0.722 0.313 0.336 0.402 0.412 
4                             0.000 0.000 0.016 0.000 0.000 0.003 
5                             0.000 0.000 0.016 0.000 0.000 0.003 
6                             0.000 0.000 0.000 0.000 0.016 0.003 
7                             0.000 0.008 0.000 0.000 0.000 0.002 
8                             0.008 0.032 0.008 0.008 0.000 0.011 
9                             0.000 0.000 0.008 0.008 0.008 0.005 
10                             0.000 0.016 0.000 0.000 0.008 0.005 
11                             0.008 0.008 0.000 0.000 0.000 0.003 
12                             0.000 0.000 0.000 0.000 0.008 0.002 
13                             0.000 0.032 0.000 0.000 0.000 0.006 
14                             0.008 0.040 0.000 0.000 0.025 0.014 
15                             0.039 0.000 0.000 0.025 0.000 0.013 
 
Numbers in brackets indicate number of chromosomes. EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo; 
1 Position from base A in initiation codon (A in ATG is considered as +1) 
2 White cell, allele observed in CYP3A4*1A; grey cell, derived allele. 
Table 8 Frequencies of variants found upstream of CYP3A7 
Region Country n 
Frequency of CYP3A7 variant 










Algeria   
Algerian 262 0.034 0.000 0.073 0.000 0.000 
Morocco   
Ifrane Berber 160 0.031 0.000 0.175 0.000 0.000 



















Ethiopia   
Afar 144 0.139 0.000 0.042 0.000 0.000 
Amhara 144 0.09 0.000 0.063 0.014 0.000 
Anuak 146 0.164 0.000 0.007 0.014 0.000 
Maale 142 0.106 0.000 0.056 0.000 0.000 
Oromo 136 0.059 0.000 0.022 0.000 0.000 
Sudan             
Various 58 0.103 0.000 0.017 0.017 0.000 
North  192 0.068 0.000 0.021 0.000 0.000 










Cameroon   
Lake Chad 230 0.213 0.000 0.026 0.009 0.000 
Mayo Darle 214 0.215 0.000 0.033 0.005 0.000 
Mambila 130 0.077 0.000 0.031 0.000 0.000 
Ghana             
Asante 66 0.121 0.000 0.000 0.000 0.000 
Bulsa 144 0.097 0.000 0.000 0.000 0.000 
Kasena 54 0.056 0.000 0.000 0.000 0.000 
Nigeria   
Igbo 158 0.101 0.000 0.000 0.000 0.000 
Senegal   
Manjak 120 0.158 0.000 0.000 0.017 0.000 
















Congo   














Malawi   
Chewa 178 0.089 0.000 0.006 0.000 0.000 
Tumbuka 112 0.161 0.000 0.000 0.000 0.000 
Yao 106 0.085 0.000 0.000 0.000 0.000 
Various 92 0.141 0.000 0.000 0.012 0.000 
Mozambique   
Sena 122 0.180 0.000 0.000 0.000 0.000 
Various 66 0.197 0.000 0.000 0.000 0.000 
South Africa   
Bantu Speakers 74 0.135 0.000 0.000 0.000 0.000 
Tanzania   
Chagga 96 0.135 0.000 0.010 0.000 0.000 
Uganda   
Bantu Speakers 78 0.154 0.000 0.000 0.000 0.000 
Zimbabwe   









Israel   
Sephardi Jews 124 0.000 0.008 0.000 0.000 0.000 
Yemen             
Hadramaut 152 0.020 0.013 0.013 0.000 0.000 







Armenia   
Armenian 142 0.000 0.000 0.028 0.000 0.000 
Netherlands   
Friesians 166 0.000 0.000 0.036 0.000 0.006 
Turkey   
Anatolian 130 0.000 0.008 0.008 0.000 0.000 
United Kingdom   
British             
  162 0.000 0.000 0.043 0.000 0.006 
Ukraine   
Ashkenazi Jews 166 0.000 0.012 0.012 0.000 0.000 
 
n represents the number of chromosomes. 
Table 9 Allele frequencies of CYP3A7*1C, CYP3A5*3, CYP3A5*6, CYP3A5*7 in Algerians and Moroccan Berbers. 
Population CYP3A7*1C CYP3A5*3 CYP3A5*6 CYP3A5*7 
Algerians (254) 0.075 0.862 0.047 0.008 
Moroccan Berbers (156) 0.179 0.859 0.038 0.000 
 Numbers in brackets indicate the number of chromosomes. 
Table 10 CYP3A7/CYP3A5 haplotypes inferred within Algerians and Moroccan Berbers. 
CYP3A variant CYP3A7*1C CYP3A5*6 CYP3A5*3 CYP3A5*7 
Haplotype frequency 












1         0.126 0.141 
2         0.008 0.000 
3         0.744 0.641 
4         0.047 0.038 
5         0.004 0.000 
6         0.071 0.179 
 
Numbers in brackets indicate the number of chromosomes. 
1 White cell, allele observed in CYP3A7*1A or CYP3A5*1A; grey cell, derived allele. 
Table 11 Putative phenotypes for haplotypes containing CYP3A7*1C and CYP3A4 regulation variants. 
Haplotype Variants defining haplotype Hypothesised Expression 
Haplotype Frequency 
Afar (120) Amhara (120) Anuak (118) Maale (120) Oromo (112) 
13 CYP3A7*1C and CYP3A4*1A 
↑ CYP3A7   
0.025 0.067 0.008 0.042 0.009 
14 CYP3A7*1C and CYP3A4 -333T 
↑ CYP3A7  ↓ CYP3A4 
0.000 0.000 0.000 0.017 0.000 
15 CYP3A7*1C and CYP3A4*1B 
↑ CYP3A7  ↑ CYP3A4 
0.000 0.000 0.000 0.000 0.009 
 
Numbers in brackets indicate the number of chromosomes. Upward arrows indicate a putative increase in expression associated with haplotype, downward 
arrows indicate a putative decrease in expression associated with haplotype. 
Table 12 Location of putative transcription factor binding sites predicted to be created/destroyed/unchanged by CYP3A7*1D. 
Transcription Factor Prediction Tool Position CSS MSS Predicted effect of CYP3A7*1D  
GRE MATCH -53/-58 0.97 0.92 Site created 
AHR MATCH -55/-47 1.00 0.98 Site destroyed 
C/EBP MATCH -51/-34 0.94 0.91 Site unchanged 
 
GRE, glucocorticoid response element; AHR, aryl hydrocarbon receptor binding site; C/EBP, CCAAT enhancer binding protein site; CSS, core similarity 
score; MSS, matrix similarity score. 
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Supplementary Material S1 
 
Table S1 Details of samples used for the geographic survey of variants associated with adult 
expression of CYP3A7 
Country N Cultural ID Collection Location 
Algeria 131 Not specified Port Say, Mostaganem, Oran 










































Duwa, Tembo, Malunga, Zora, Chirengi 
Netherlands 83 Friesian Friesland 

















Tanzania 48 Chagga Kilimanjaro 
Turkey 65 Anatolian Turks West and East Anatolia 
Uganda 39 Bantu speakers Ssese 
Ukraine 83 Ashkenazi Jews Diaspora and Israel 





Sena and Msila 
Hadramaut 
Zimbabwe 41 Shona Mposi 
N represents the number of individuals. 
 
 
Supplementary Material S2 
Amplification and sequencing CYP3A4 exons 1 to 7 
 
Primers designed to amplify CYP3A4 exons 1 to 7 and regions of flanking adjacent 
introns are provided in Table S2. 
 
DNA was amplified within 96-well plates in 10 µl reaction volumes containing 1 µl (~ 
1 ng) of template DNA, 0.5 µM of each oligonucleotide, 0.2 µM dNTPs, 0.2 units Taq 
DNA polymerase (HT Biotechnology, Cambridge, UK) and 1x reaction buffer (10 mM 
Tris-HCl, pH 9.0, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 0.01% gelatin). The 
cycling parameters for amplification were: an initial denaturation step of 5 minutes at 
94ºC, followed by 35 cycles of denaturation at 94ºC for 30 seconds, annealing at the 
temperatures provided in Table S2 for 30 seconds and extension at 72ºC for 30 
seconds. A final extension step at 72ºC for 10 minutes completed the cycle.  
 
The PCR product was purified by mixing with 30 μl of 1/3 water 2/3 home-made 
micro clean (HM-MC) (40 % PEG-8000, 1 M NaCl, 2 mM Tris-HCl (pH 7.5), 0.2 mM 
EDTA, 3.5 mM MgCl2), followed by centrifugation at 4000 g for 60 minutes, removal 
of the supernatant and addition of 150 µl of 70% ethanol. This was followed by 
further centrifugation at 4000 g for 25 min and removal of the supernatant. Samples 
were dried at 65 ºC for 5 minutes and resuspended in 10 µl distilled water. This 
purified PCR product was used as the DNA template for sequencing reactions. 
 
Bidirectional sequencing of purified PCR products was conducted using the primers 
detailed in Table S2. DNA was sequenced in 96-well plates in 10 µl reaction volumes 
containing 6 µl of the purified PCR product, 0.32 μl of either primer (at 5 µM), 0.32 µl 
of BigDye termination mix v3.1 (BigDye® Terminator v3.1 Cycle Sequencing Kit, 
Applied Biosystems (ABI), Warrington UK) and 2.15 µl of Better Buffer (Applied 
Biosystems (ABI), Warrington UK). The cycling parameters were: an initial step of 96 
ºC for 1 minute followed by 25 cycles of 96 ºC for 10 seconds, 55 ºC for 10 seconds 
and 60 ºC for 4 minutes.  
 
Sequencing products were purified by ethanol precipitation. To each 10 µl reaction 
2.5 µl of 125 mM EDTA was added, followed by 30 µl of 100% ethanol and 
centrifugation at 4000 g for 60 minutes. The supernatant was removed and a further 
30 µl of 70% ethanol added followed by centrifugation for 10 minutes and removal of 
the supernatant. Samples were dried at 65 ºC for 5 minutes. Each sample was 
subsequently mixed with 10 µl of high purity formamide, heated at 96 ºC for five 
minutes, cooled on ice and subsequently run on an ABI 3730 genetic analyser. 
Sequence traces were analysed using Sequencher 4.1.10 software (Gene Codes 
Corporation, USA). 
 
Amplification and sequencing of CYP3A4 exons 8 to 13, the 5’ regulatory 
region and 3’ UTR 
 
CYP3A4 exons 8 to 13 (and regions of flanking adjacent introns), the 3’ UTR and 5’ 
regulatory regions were initially sequenced by Macrogen (www.Macrogen.com). 3.2 
ng of genomic DNA template was sent to Macrogen for PCR amplification and 
sequencing in 96-well plates. Sequencing conducted by Macrogen was in the 
forward direction only. Sequence traces were analysed using Sequencher 4.1.10 
software (Gene Codes Corporation, USA).  
 
Primers used for PCR amplification and sequencing of exons 8 to 13 and the 3’ UTR 
are provided in Table S2. PCR amplification and sequencing (bi-directional 
sequencing) was repeated for all identifications of novel variation using the methods 
described for exons 1 to 7.  
 
The 5’ regulatory regions sequenced comprised the CYP3A4 promoter and the two 
upstream CYP3A4 enhancers: the xenobiotic responsive enhancer module (XREM) 
and the constitutive liver enhancer module 4 (CLEM4).  These regions are highly 
conserved functional DNA sequences containing clusters of binding sites for 
transcription factors that regulate CYP3A4. This upstream arrangement is unique to 
the CYP3A family (Qiu et al., 2010).  
 
The promoter (-500 nucleotides), XREM (-7.7 kb/-7.9 kb) and CLEM4 (-10.9 kb/ -
11.4 kb) were sequenced using primers detailed in Table S2. 
Table S2 Primers for PCR amplification and sequencing of the CYP3A4 promoter, upstream 
enhancers, exons (and flanking regions of adjacent introns) and the 3’ UTR.  
Region 
Amplified 























































































































































Exon 13  







* denotes exons for which a different set of primers were used during sequencing.
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Frequencies of haplotypes are included in Table S3. Blue 
cell, presence of non-CYP3A4*1A allele; white cell, allele 
observed in CYP3A4*1A; red cell, non synonymous variant 
predicted to impact protein structure/function; grey cell, 
putative splice variant. 
 
Table S3 Frequencies of CYP3A4 entire gene haplotypes within individual populations 
Haplotype 
ID 
ASW CEPH CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI EAF EAN EAM EML EOR 
1 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 
2 
0.06 0.00 0.00 0.00 0.06 0.03 0.03 0.00 0.00 0.16 0.00 0.01 0.02 0.09 0.01 0.00 0.01 0.01 0.02 
3 
0.11 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.02 0.00 0.00 0.10 0.00 0.00 0.00 0.00 0.00 
4 
0.01 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
5 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
6 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
7 
0.05 0.03 0.12 0.10 0.00 0.03 0.04 0.07 0.08 0.06 0.14 0.03 0.05 0.07 0.00 0.00 0.00 0.01 0.00 
8 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
9 
0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
10 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
11 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
12 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
13 
0.01 0.00 0.11 0.12 0.05 0.00 0.00 0.00 0.00 0.01 0.07 0.06 0.00 0.01 0.03 0.00 0.00 0.00 0.00 
14 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
15 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.02 
16 
0.04 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.16 0.01 0.02 0.00 0.07 0.14 0.13 0.11 0.05 0.07 
17 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 
18 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
19 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
20 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 
21 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.00 0.00 0.00 
22 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
23 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
24 
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.03 0.01 0.05 0.00 
25 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
26 
0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.03 0.00 0.01 0.00 0.00 0.01 
27 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
28 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
29 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
30 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 
31 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
32 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
33 
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
34 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.00 
35 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
36 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.02 0.01 
37 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
38 
0.00 0.00 0.10 0.07 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.03 0.03 0.01 
39 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
40 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
41 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 
42 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 
43 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
44 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
45 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
46 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
47 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
48 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
49 
0.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.04 0.00 0.17 0.00 0.01 0.00 0.00 0.00 
50 
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
51 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
52 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
53 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.01 0.00 0.00 0.00 
54 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
55 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
56 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
57 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
58 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
59 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
60 
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 
61 
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
62 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
63 
0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
64 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.01 0.00 0.00 0.00 
65 
0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 
66 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
67 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
68 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
69 
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.02 0.00 0.01 0.00 0.01 0.00 0.00 0.00 
70 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
71 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
72 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
73 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
74 
0.00 0.00 0.01 0.03 0.09 0.00 0.00 0.04 0.01 0.00 0.14 0.02 0.00 0.00 0.00 0.00 0.03 0.01 0.01 
75 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
76 
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
77 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
78 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
79 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 
80 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 
81 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 
82 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
83 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
84 
0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.02 0.03 0.04 0.05 
85 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
86 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.03 0.03 0.01 0.03 
87 
0.03 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.05 0.00 0.01 0.00 0.03 0.02 0.07 0.01 0.03 0.05 
88 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 
89 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
90 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
91 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 
92 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
93 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 
94 
0.20 0.86 0.63 0.67 0.63 0.84 0.85 0.82 0.67 0.05 0.56 0.62 0.84 0.07 0.36 0.05 0.34 0.15 0.32 
95 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.03 0.00 0.00 
96 
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
97 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
98 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
99 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.04 
100 
0.00 0.00 0.02 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
101 
0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
102 
0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
103 
0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
104 
0.02 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.01 0.00 
105 
0.00 0.00 0.00 0.00 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
106 
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
107 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
108 
0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
109 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
110 
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
111 
0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
112 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
113 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
114 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.03 0.01 0.01 0.02 
115 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 
116 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
117 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 
118 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.02 
119 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 
120 
0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
121 
0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
122 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.00 
123 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
124 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
125 
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
126 
0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.02 0.01 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 
127 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
128 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
129 
0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.04 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
130 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 
131 
0.00 0.02 0.00 0.00 0.00 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 
132 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
133 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 
134 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
135 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.07 0.03 0.05 0.01 
136 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
137 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.01 
138 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
139 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.01 0.06 0.04 0.03 
140 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 
141 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 
142 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 
143 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
144 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
145 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 
146 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
147 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 
148 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 
149 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
150 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.13 0.02 0.02 0.03 
151 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 
152 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
153 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 
154 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
155 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 
156 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
157 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
158 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
159 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.01 
160 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 
161 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
162 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
163 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
164 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
165 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
166 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
167 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
168 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
169 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
170 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
171 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.02 0.02 
172 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 
173 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
174 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
175 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
176 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
177 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 
178 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
179 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 
180 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.04 0.01 0.03 0.00 
181 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
182 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
183 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
184 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 
185 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
186 
0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
187 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
188 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
189 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
190 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
191 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 
192 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
193 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
194 
0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
195 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 
196 
0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.04 0.00 0.00 0.00 0.01 0.02 0.00 0.01 0.00 0.01 0.01 0.01 
197 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
198 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.01 0.02 0.02 
199 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 
200 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
201 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 
202 
0.03 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
203 
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
Haplotype IDs shaded in blue are those unique to Ethiopia, those shaded in green are unique to 
African populations. Population codes: ASW, African American; CEU, European; CHB, Han Chinese; 
CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, 
Japanese; LWK, Luhya; MXL, Mexican American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; 
EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo 
 
 
Table S4 Nucleotide diversity (π) of CYP3A4 gene regions for individual populations in ascending order 
 
SD, standard deviation of π; K, average number of pairwise differences. ASW, African American; CEU, European; CHB, Han Chinese; CHS, Southern Han 
Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican American; PUR, Puerto Rican; TSI, 




 Supplementary Figure S2 Population pairwise genetic distances (lower triangle) and P values (upper triangle) for CYP3A4 entire gene haplotypes 
 
P values below and above the 5% significance threshold are highlighted in red and blue respectively. Populations: ASW, African American; CEU, European; 
CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican 






ASW CEU CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI EAF EAM EAN EML EOR
ASW <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CEU 0.3077 <0.0001 <0.0001 <0.0001 0.5100 0.4100 0.6500 <0.0001 <0.0001 <0.0001 <0.0001 0.5900 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHB 0.1478 0.0888 0.5400 <0.0100 <0.0001 <0.0001 <0.0500 <0.0100 <0.0001 <0.0100 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHS 0.1688 0.0663 -0.0011 <0.0500 <0.0001 <0.0001 0.0800 <0.0001 <0.0001 <0.0001 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CLM 0.1274 0.0829 0.0304 0.0220 <0.0001 <0.0001 <0.0500 <0.0001 <0.0001 <0.0100 0.1200 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
FIN 0.2945 -0.0013 0.0811 0.0595 0.0666 0.7600 0.6400 <0.0001 <0.0001 <0.0001 <0.0001 0.7300 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
GBR 0.3013 -0.0007 0.0837 0.0619 0.0741 -0.0030 0.5500 <0.0001 <0.0001 <0.0001 <0.0001 0.5300 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
IBS 0.1966 -0.0072 0.0391 0.0230 0.0304 -0.0086 -0.0067 0.0600 <0.0001 <0.0001 0.0600 0.8600 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
JPT 0.1782 0.0817 0.0147 0.0211 0.0456 0.0741 0.0772 0.0382 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
LWK 0.0281 0.3731 0.2210 0.2443 0.1958 0.3595 0.3646 0.2715 0.2511 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
MXL 0.1088 0.1266 0.0243 0.0237 0.0186 0.1167 0.1204 0.0528 0.0550 0.1768 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PUR 0.1121 0.0744 0.0157 0.0104 0.0045 0.0633 0.0691 0.0254 0.0353 0.1864 0.0198 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
TSI 0.2961 -0.0019 0.0765 0.0556 0.0707 -0.0029 -0.0018 -0.0111 0.0711 0.3621 0.1122 0.0630 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
YRI 0.0077 0.3604 0.2048 0.2283 0.1846 0.3486 0.3538 0.2555 0.2357 0.0110 0.1603 0.1709 0.3503 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
EAF 0.0415 0.2104 0.0832 0.0964 0.0661 0.1977 0.2048 0.1268 0.1060 0.0726 0.0630 0.0557 0.1991 0.0719 <0.0001 0.5500 <0.0001 0.2300
EAM 0.0472 0.3773 0.2188 0.2421 0.1935 0.3655 0.3718 0.2642 0.2480 0.0341 0.1742 0.1824 0.3678 0.0390 0.0574 <0.0001 <0.0001 <0.0001
EAN 0.0353 0.2149 0.0867 0.1008 0.0658 0.2019 0.2089 0.1288 0.1062 0.0671 0.0607 0.0588 0.2036 0.0645 -0.0014 0.0519 <0.0001 0.3500
EML 0.0263 0.3104 0.1556 0.1774 0.1344 0.2981 0.3048 0.2038 0.1816 0.0373 0.1177 0.1254 0.3001 0.0335 0.0278 0.0160 0.0206 <0.0001
EOR 0.0310 0.2205 0.0909 0.1054 0.0690 0.2071 0.2142 0.1322 0.1130 0.0641 0.0648 0.0612 0.2088 0.0591 0.0015 0.0477 0.0006 0.0181
CYP3A4 entire gene haplotypes 
Supplementary Figure S3 Population pairwise genetic distances (lower triangle) and P values (upper triangle) for CYP3A4 exonic haplotypes 
 
P values below and above the 5% significance threshold are highlighted in red and blue respectively. Populations: ASW, African American; CEU, European; 
CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican 






ASW CEU CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI EAF EAM EAN EML EOR
ASW <0.050 <0.010 0.063 0.162 <0.050 <0.050 0.342 0.117 0.360 <0.050 0.99 <0.010 0.153 0.360 0.505 0.324 <0.050 0.189
CEU 0.032 0.459 0.342 0.676 0.162 0.162 0.991 <0.050 <0.001 0.991 <0.010 0.991 <0.001 0.063 <0.001 <0.001 <0.001 <0.001
CHB 0.048 0.001 0.252 0.180 <0.050 <0.050 0.991 <0.001 <0.001 0.441 <0.010 0.477 <0.001 <0.050 <0.001 <0.001 <0.001 <0.001
CHS 0.021 0.000 0.006 0.649 0.225 0.162 0.991 0.180 <0.001 0.559 <0.050 0.604 <0.001 0.180 <0.001 <0.001 <0.001 <0.001
CLM 0.009 -0.002 0.010 -0.002 0.775 0.477 0.991 0.198 <0.010 0.604 0.144 0.856 <0.010 0.505 0.108 <0.050 <0.001 <0.050
FIN 0.011 0.004 0.013 0.001 -0.003 0.459 0.991 0.189 <0.050 0.225 <0.010 0.198 <0.001 0.378 <0.050 <0.001 <0.001 <0.010
GBR 0.014 0.004 0.014 0.001 -0.002 -0.001 0.991 0.126 <0.001 0.288 <0.050 0.207 <0.001 0.333 <0.050 <0.001 <0.001 <0.001
IBS 0.005 -0.018 0.000 -0.014 -0.015 -0.010 -0.010 0.613 0.252 0.991 0.396 0.991 0.072 0.703 0.387 0.144 0.135 0.198
JPT 0.008 0.015 0.024 0.006 0.004 0.003 0.005 -0.004 <0.010 0.090 0.081 <0.050 <0.001 0.225 0.081 <0.001 <0.001 <0.050
LWK -0.001 0.040 0.051 0.031 0.020 0.021 0.024 0.013 0.015 <0.001 0.505 <0.001 0.099 0.081 0.279 0.333 <0.050 0.180
MXL 0.023 -0.003 0.003 -0.001 -0.002 0.003 0.003 -0.017 0.010 0.033 <0.050 0.991 <0.001 0.135 <0.010 <0.001 <0.001 <0.001
PUR -0.008 0.039 0.057 0.026 0.013 0.015 0.016 0.008 0.010 -0.003 0.030 <0.050 0.099 0.261 0.378 0.450 0.126 0.144
TSI 0.022 -0.002 0.003 -0.001 -0.004 0.002 0.003 -0.016 0.011 0.033 -0.003 0.029 <0.001 0.189 <0.001 <0.001 <0.001 <0.001
YRI 0.010 0.072 0.086 0.064 0.045 0.048 0.052 0.033 0.038 0.006 0.060 0.008 0.066 <0.001 0.06 0.505 0.568 0.108
EAF 0.001 0.010 0.020 0.004 -0.002 0.000 0.001 -0.008 0.002 0.011 0.006 0.003 0.004 0.033 0.387 <0.050 <0.010 <0.050
EAM -0.002 0.028 0.040 0.019 0.011 0.010 0.013 0.003 0.005 0.002 0.020 -0.002 0.023 0.012 0.002 0.126 <0.050 0.766
EAN 0.000 0.061 0.077 0.050 0.033 0.036 0.040 0.024 0.027 -0.001 0.050 -0.002 0.053 -0.002 0.021 0.006 0.297 0.126
EML 0.016 0.084 0.101 0.075 0.053 0.057 0.062 0.038 0.045 0.009 0.071 0.011 0.078 -0.002 0.040 0.018 0.000 0.072
EOR 0.004 0.043 0.056 0.034 0.023 0.021 0.025 0.012 0.014 0.003 0.034 0.003 0.038 0.008 0.010 -0.004 0.006 0.011
CYP3A4 exonic haplotypes
Supplementary Figure S4 Population pairwise genetic distances (lower triangle) and P values (upper triangle) for CYP3A4 3’ UTR haplotypes 
 
P values below and above the 5% significance threshold are highlighted in red and blue respectively. Populations: ASW, African American; CEU, European; 
CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican 
American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo.
ASW CEPH CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI EAF EAN EAM EML EOR
ASW 0.1500 <0.0001 <0.0001 0.0600 0.0600 <0.0500 0.6000 <0.0001 0.0700 <0.0500 0.2700 0.0800 0.4400 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CEPH 0.0059 <0.0001 <0.0001 <0.0100 0.4300 0.1500 0.9900 <0.0001 0.1400 0.1900 0.4000 0.6200 0.1500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHB 0.0616 0.0346 0.4800 0.5900 <0.0001 <0.0500 <0.0500 0.6700 <0.0001 <0.0500 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHS 0.0749 0.0436 0.0002 0.1400 <0.0001 <0.0100 <0.0100 0.2900 <0.0001 <0.0100 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CLM 0.0274 0.0145 0.0011 0.0100 0.1400 0.5200 0.2300 0.6300 0.1200 0.5000 0.3600 0.1400 0.0900 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
FIN 0.0117 -0.0019 0.0254 0.0340 0.0067 0.5400 0.7600 <0.0500 0.6400 0.3500 0.4600 0.9900 0.2600 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
GBR 0.0194 0.0037 0.0110 0.0186 -0.0020 -0.0016 0.2900 0.0900 0.2300 0.9400 0.6700 0.4400 0.2300 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
IBS -0.0090 -0.0197 0.1010 0.1722 0.0254 -0.0162 -0.0026 <0.0500 0.5100 0.2300 0.6200 0.9900 0.5200 0.0600 <0.0001 <0.0001 <0.0001 <0.0500
JPT 0.0483 0.0261 -0.0031 0.0067 -0.0015 0.0181 0.0058 0.0587 <0.0100 0.1900 0.0900 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
LWK 0.0137 0.0039 0.0328 0.0422 0.0109 -0.0027 0.0018 -0.0100 0.0248 0.2300 0.2200 0.3600 0.2100 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
MXL 0.0203 0.0062 0.0120 0.0223 -0.0023 0.0005 -0.0053 0.0030 0.0058 0.0031 0.5200 0.2900 0.2600 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PUR 0.0040 -0.0009 0.0212 0.0337 0.0004 -0.0018 -0.0035 -0.0099 0.0121 0.0035 -0.0016 0.3900 0.7100 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
TSI 0.0112 -0.0028 0.0260 0.0343 0.0079 -0.0051 -0.0007 -0.0174 0.0189 -0.0015 0.0016 -0.0017 0.2900 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
YRI -0.0009 0.0025 0.0289 0.0378 0.0073 0.0007 0.0029 -0.0098 0.0210 0.0022 0.0037 -0.0044 0.0011 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
EAF 0.0824 0.1014 0.1918 0.2047 0.1426 0.1257 0.1411 0.0607 0.1745 0.1330 0.1320 0.1093 0.1243 0.1159 <0.0001 0.45 <0.0001 0.7400
EAN 0.2312 0.2717 0.3719 0.3850 0.3039 0.3024 0.3180 0.1881 0.3515 0.3096 0.2961 0.2660 0.3032 0.2872 0.0624 <0.0001 0.0500 <0.0001
EAM 0.0875 0.1096 0.1984 0.2106 0.1487 0.1344 0.1496 0.0640 0.1815 0.1415 0.1389 0.1157 0.1334 0.1241 -0.0025 0.0478 <0.0100 0.9500
EML 0.1786 0.2146 0.3100 0.3223 0.2472 0.2441 0.2592 0.1387 0.2909 0.2518 0.2395 0.2112 0.2445 0.2305 0.0414 0.0046 0.0247 <0.0100
EOR 0.0835 0.1046 0.1957 0.2084 0.1453 0.1296 0.1452 0.0604 0.1783 0.1369 0.1350 0.1116 0.1284 0.1194 -0.0043 0.0537 -0.0057 0.0291
CYP3A4 3' UTR haplotypes
Supplementary Figure S5 Population pairwise genetic distances (lower triangle) and P values (upper triangle) for CYP3A4 5’ regulatory region 
haplotypes 
 
P values below and above the 5% significance threshold are highlighted in red and blue respectively. Populations: ASW, African American; CEU, European; 
CHB, Han Chinese; CHS, Southern Han Chinese; CLM, Columbian; FIN, Finnish; GBR, British; IBS, Spanish; JPT, Japanese; LWK, Luhya; MXL, Mexican 
American; PUR, Puerto Rican; TSI, Tuscan; YRI, Yoruba; EAF, Afar; EAM, Amhara; EAN, Anuak; EML, Maale; EOR, Oromo. 
ASW CEPH CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI EAF EAN EAM EML EOR
ASW <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0500 <0.0001 <0.0001 <0.0001 <0.0100 <0.0001
CEPH 0.5079 0.1300 0.1200 <0.0001 0.5400 0.3200 0.9900 0.1400 <0.0001 0.1300 <0.0001 0.3100 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHB 0.5569 0.0128 0.9900 <0.0001 <0.0500 <0.0001 0.9900 0.4700 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CHS 0.5616 0.0132 0.0000 <0.0001 <0.0001 <0.0001 0.9900 0.4100 <0.0001 <0.0001 <0.0001 <0.0100 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CLM 0.3333 0.0644 0.1218 0.1240 <0.0500 <0.0500 0.0800 <0.0001 <0.0001 <0.0500 0.0800 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
FIN 0.4887 -0.0010 0.0278 0.0284 0.0371 0.7900 0.5600 <0.0500 <0.0001 0.2900 <0.0001 0.9900 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
GBR 0.4707 0.0031 0.0358 0.0365 0.0265 -0.0048 0.5900 <0.0500 <0.0001 0.4400 <0.0001 0.7900 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
IBS 0.3645 -0.0108 0.0000 0.0000 0.0440 -0.0016 0.0028 0.9900 <0.0001 0.3900 <0.0500 0.6300 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
JPT 0.5349 0.0046 0.0005 0.0007 0.1015 0.0179 0.0249 -0.0177 <0.0001 <0.0100 <0.0001 <0.0500 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
LWK 0.0709 0.6638 0.6980 0.7013 0.5286 0.6498 0.6366 0.5652 0.6829 <0.0001 <0.0001 <0.0001 <0.0500 <0.0001 0.1200 <0.0001 <0.0001 <0.0001
MXL 0.4135 0.0104 0.0437 0.0447 0.0161 0.0003 -0.0019 0.0038 0.0308 0.5954 <0.0001 0.3700 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PUR 0.2208 0.1646 0.2311 0.2347 0.0203 0.1300 0.1124 0.1040 0.2066 0.4248 0.0837 <0.0001 <0.0001 <0.0001 <0.0001 <0.0500 <0.0001 <0.0001
TSI 0.4903 -0.0003 0.0262 0.0267 0.0353 -0.0050 -0.0046 -0.0021 0.0171 0.6510 -0.0008 0.1278 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
YRI 0.0144 0.5687 0.6071 0.6109 0.4228 0.5542 0.5396 0.4537 0.5897 0.0156 0.4924 0.3180 0.5561 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
EAF 0.0669 0.3141 0.3638 0.3679 0.1531 0.2909 0.2737 0.2174 0.3435 0.2234 0.2316 0.0653 0.2910 0.1405 <0.0001 0.4700 0.1200 0.8900
EAN 0.1155 0.7382 0.7736 0.7766 0.5970 0.7223 0.7087 0.6363 0.7582 0.0057 0.6669 0.4876 0.7225 0.0455 0.2672 <0.0001 <0.0001 <0.0001
EAM 0.0910 0.2755 0.3257 0.3296 0.1192 0.2513 0.2343 0.1882 0.3057 0.2635 0.1951 0.0401 0.2512 0.1735 -0.0020 0.3099 <0.0500 0.2600
EML 0.0300 0.4139 0.4641 0.4685 0.2401 0.3916 0.3734 0.2995 0.4431 0.1435 0.3260 0.1331 0.3925 0.0802 0.0100 0.1798 0.0256 0.1400
EOR 0.0639 0.3362 0.3880 0.3923 0.1679 0.3122 0.2942 0.2334 0.3669 0.2160 0.2502 0.0749 0.3122 0.1350 -0.0057 0.2597 0.0018 0.0067
CYP3A4 5' regulatory region haplotypes
Table S5. Results of neutrality tests performed on CYP3A4 variation in populations of Ethiopia 
and The 1000 Genomes Project 
  
All CYP3A4 variants, including singletons, were included; n represents the number of chromosomes. 
D (P value) D* (P value) F* (P value)
ASW 122 -1.01 (>0.10) -1.70 (>0.10) -1.70 (>0.10)
CEU 174 -1.83 (<0.05) -1.12 (>0.10) -1.66 (>0.10)
CHB 194 -0.90 (>0.10) -3.74 (<0.02) -3.23 (<0.02)
CHS 200 -0.51 (>0.10) -1.44 (>0.10) -1.32 (>0.10)
CLM 120 -1.56 (>0.05) -3.61 (<0.02) -3.38 (<0.02)
FIN 186 -1.80 (<0.05) -1.45 (>0.10) -1.90 (>0.10)
GBR 178 -1.92 (<0.05) -3.35 (<0.02) -3.36 (<0.02)
IBS 28 -1.06 (>0.10) -0.58 (>0.10) -0.83 (>0.10)
JPT 178 -0.73 (>0.10) -0.19 (>0.10) -0.46 (>0.10)
LWK 194 -1.31 (>0.10) -0.77 (>0.10) -1.96 (>0.10)
MXL 132 -1.15 (>0.10) -2.22 (>0.05) -2.17 (>0.05)
PUR 110 -1.48 (>0.10) -3.10 (<0.05) -2.95 (<0.05)
TSI 196 -1.95 (<0.05) -3.54 (<0.02) -3.51 (<0.02)
YRI 176 -1.19 (>0.10) -0.57 (>0.10) -0.99 (>0.10)
EAF 152 -0.50 (>0.10) -0.54 (>0.10) -0.63 (>0.10)
EAM 152 -1.00 (>0.10) -1.06 (>0.10) -1.24 (>0.10)
EAN 152 -0.75 (>0.10) -0.15 (>0.10) -0.48 (>0.10)
EML 150 -0.87 (>0.10) -1.78 (>0.10) -1.68 (>0.10)
EOR 146 -1.08 (>0.10) -2.39 (<0.05) -2.22 (>0.05)
Population
Tajimas D Fu and Li's Test
n
Supplementary Material S4 
LD plots are provided for each individual population and for the combined world 
dataset. The strength of LD is based on D’ and LOD (logarithm of the odds) scores 
and increases with colour from white to blue to red as depicted in Key 1. The first 
row of numbers along the top of the plot denotes the chromosome position in Human 
Reference Assembly 36.2 of each variant (see Tables 1 and 2). The space between 
loci is indicated by the white bar at the top of the plot. Numbers within squares are D’ 
values (multiplied 100-fold). Empty squares indicate D’ of 1. Singletons and low 
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